Lead the Path to Autoimmune Innovation
The 3rd Cell Therapy for Autoimmune Disease Summit, connected a community of 130+ strong scientific pioneers, C-suite executives, VPs and directors driving innovative cell therapies across a wealth of autoimmune indications.
Attendees delved into the latest data, shared proven strategies and unpacked first-hand experiences to propel their pipeline from preclinical innovation to clinical success. Featuring a 80% new speaker faculty, 11 new companies and preclinical and clinical showcases, guests were represented at the only meeting translating cell therapy potential in autoimmunity into reality.
What You Missed in 2025:
3 days of immersive tailored learning, no matter your stage of development, our tracked structure extended to the workshop day. Whether you were pivoting from oncology or were a seasoned expert in autoimmunity, you delved into solutions addressing your most pressing challenges.
Deep dives into rapidly emerging in vivo therapies, and how these reshaped the course for autoimmune pipelines.
Bridged the gap between science and strategy in our search and evaluation pharma insights panel. We helped align your pipeline expansion with industry developments and uncovered new partnership opportunities.
Accessed a breadth of content, from preclinical and translational to clinical development, to keynote presentations and discussions, we equipped your scientific and corporate development teams for therapeutic success.
We Empowered Your Team to Accelerate Clinical Success in 2025:
To maximize your team's take home learnings and enhance cross-functional collaborations, the 2025 agenda was expertly curated across two tracks. We attracted representation from C-suite leaders to scientific and business development teams, and fast-tracked your pipeline progression!
Preclinical & Translational Track
Clinical Track
Who Did You Meet in 2025?
Hear It Straight from Your Peers:
This meeting had outstanding, high-quality speakers, with expertise in their areas. It was a collaborative environment with many opportunities to network and discuss
Chief Executive Officer, iCell Gene Therapeutics, Past Attendee
I learned an incredible amount about the space from the summit. It was helpful to hear perspectives from investors, physicians, and researchers, all in one room
Associate Director, Sanguine Bio, Past Attendee
